FDA’s final CMC guidance sets expectations for manufacturing and quality for human gene therapy INDs. This article reviews existing analytical applications, focusing on viral vector characterization of impurities.
Jie Ding
Advertisement
Articles by Jie Ding
Advertisement
Latest Updated Articles
Viral Vector API Characterization of Product-Related ImpuritiesPublished: October 16th 2020 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
A-TEEM: A Novel, Powerful Tool for Evaluating and Monitoring Cell Culture Media
2
CPHI Frankfurt 2025 Highlights Global Pharma Innovation and Manufacturing Leadership
3
Global Study Confirms Survival Advantage of Mogamulizumab in Advanced Mycosis Fungoides and Sézary Syndrome
4
Behind the Headlines Episode 27: Unpacking Mega Deals and R&D Directions
5
